John Newman Recent News
Safety Remains A Top Concern For Kite Pharma After Positive Phase 1 ZUMA-1 Data
Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market
Canaccord Sees $40 In Upside For Agios, Upgrades To Buy
Is Medivation's Congressional Letter Just Noise?
Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting
Canaccord Downgrading Agios To Hold
Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen
UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals on Expected Continued Pipeline Success
UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness
UPDATE: Canaccord Genuity Initiates Coverage on Medivation as Urologist Uptake is Unclear
UPDATE: Canaccord Genuity Initiates Coverage on Lpath on iSONEP Potential
UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data
Warner Chilcott Receives 2nd PIV Challenge for Asacol (WCRX)
Oppenheimer Upbeat About Questcor Pharmaceuticals (QCOR)
Oppenheimer Rates Eurand N.V. (EURX) Outperform
Oppenheimer Maintains Salix Pharmaceuticals (SLXP) Outperform Rating